Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danzhijiangtang is a Traditional Chinese Medicine (TCM) herbal formula primarily used for the treatment of type 2 diabetes mellitus and associated diabetic vascular complications. Developed by the First Affiliated Hospital of Anhui University of Chinese Medicine, the formula is designed to address the TCM syndrome of Qi-Yin deficiency and blood stasis. It typically contains active botanical ingredients such as *Moutan Cortex* (Dan Pi) and *Hirudo* (Shui Zhi/Leech). The mechanism of action involves improving microcirculation, reducing blood viscosity, and providing hypoglycemic effects. Clinical studies, including randomized controlled trials, have evaluated its efficacy in reducing vascular lesions and improving metabolic parameters in diabetic patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on danzhijiangtang.